Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739620 | 0.88 | ALDH1A1 (0.59) | ALDH1A1MAPTCYP1A2KDM4EPOLB | |
| SCHEMBL16000906 | 0.86 | ALDH1A1 (0.64) | ALDH1A1MAPTCYP1A2KDM4EPOLB | |
| SCHEMBL3983141 | 0.86 | ALDH1A1 (0.60) | ALDH1A1MAPTCYP1A2KDM4EPOLB | |
| SCHEMBL29739328 | 0.85 | ALDH1A1 (0.58) | ALDH1A1MAPTCYP1A2KDM4EPOLB | |
| SCHEMBL29739613 | 0.84 | ALDH1A1 (0.54) | ALDH1A1MAPTCYP1A2KDM4EPOLB | |
| SCHEMBL24064687 | 0.83 | ALDH1A1 (0.56) | ALDH1A1MAPTCYP1A2KDM4EPOLB | |
| SCHEMBL17868230 | 0.82 | POLB (0.67) | ALDH1A1MAPTCYP1A2KDM4EPOLB | |
| SCHEMBL29739503 | 0.82 | POLB (0.67) | ALDH1A1MAPTCYP1A2KDM4EPOLB | |
| SCHEMBL2490151 | 0.82 | POLB (0.67) | ALDH1A1MAPTCYP1A2KDM4EPOLB | |
| SCHEMBL28282044 | 0.82 | RAD51 (0.57) | ALDH1A1MAPTCYP1A2KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11572372-B2 | Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds | MEDSHINE DISCOVERY INC. (CN) | 2023-02-07 | — | — | US | disclosed |
| CN-109476668-B | 6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazines and 6, 7-dihydro-4H-triazolo [1,5-a ] pyrazines for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-109843892-B | Oxadiazepinone derivatives and their use in the treatment of hepatitis B infections | 诺维拉治疗公司 | 2022-01-25 | — | — | CN | disclosed |
| US-20210371388-A1 | Bicyclic Carboxamide with Exocyclic Urea Derivatives as Antivirals for the Treatment of HBV Infection | THE BARUCH S. BLUMBERG INSTITUTE | 2021-12-02 | — | — | US | disclosed |
| US-20200377517-A1 | ANTI-HBVTETRAHYDROISOXAZOLO[4,3-C]PYRIDINE COMPOUNDS | MEDSHINE DISCOVERY INC. (CN) | 2020-12-03 | — | — | US | disclosed |
| EP-3712139-A1 | ANTI-HBV TETRAHYDROISOXAZOLO[4,3-C]PYRIDINE COMPOUNDS | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-10683299-B2 | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | HOFFMANN LA ROCHE INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3484886-B1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-20190248792-A1 | NOVEL PYRAZOLOPYRAZINE AND TRIAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2018011163-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248792-A1 | NOVEL PYRAZOLOPYRAZINE AND TRIAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | CYP3A5, RRP15, HAVCR2 | ALDH1A1 1006/4885MAPT 3240/4885CYP1A2 9/4885 |
| US-20210371388-A1 | Bicyclic Carboxamide with Exocyclic Urea Derivatives as Antivirals for the Treatment of HBV Infection | EFTUD2, UGP2, UMPS | ALDH1A1 3793/4885MAPT 3057/4885CYP1A2 1170/4885 |
| US-10683299-B2 | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | CYP3A5, RRP15, QDPR | ALDH1A1 914/4885MAPT 3266/4885CYP1A2 6/4885 |
| US-11572372-B2 | Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds | HAVCR2, HCCS, CD4 | ALDH1A1 3483/4885MAPT 3654/4885CYP1A2 264/4885 |
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | CRBN, GSPT1, GSPT2 | ALDH1A1 4088/4885MAPT 3269/4885CYP1A2 4774/4885 |
| US-20200377517-A1 | ANTI-HBVTETRAHYDROISOXAZOLO[4,3-C]PYRIDINE COMPOUNDS | HAVCR2, HCCS, CD4 | ALDH1A1 3483/4885MAPT 3654/4885CYP1A2 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.